Education
About Us
Working with TipRanks
Follow Us
Precipio Inc (PRPO)
NASDAQ:PRPO
PRPO Stock Chart & Stats
$23.29
$0.30(5.08%)
At close: 4:00 PM EST
$23.29
$0.30(5.08%)
Day’s Range― - ―
52-Week Range$3.90 - $28.50
Previous CloseN/A
Volume11.00
Average Volume (3M)19.92K
Market Cap
$40.47M
Enterprise Value$19.17M
Total Cash (Recent Filing)$2.31M
Total Debt (Recent Filing)$3.51M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Apr 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding1,752,007
10 Day Avg. Volume16,445
30 Day Avg. Volume19,918
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.67
Price to Sales (P/S)0.51
P/FCF Ratio37.59
Enterprise Value/Market Cap0.47
Enterprise Value/Revenue0.89
Enterprise Value/Gross Profit1.88
Enterprise Value/Ebitda52.82
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Precipio News
PRPO FAQ
What was Precipio Inc’s price range in the past 12 months?
Precipio Inc lowest stock price was $3.90 and its highest was $28.50 in the past 12 months.
What is Precipio Inc’s market cap?
Precipio Inc’s market cap is $40.47M.
When is Precipio Inc’s upcoming earnings report date?
Precipio Inc’s upcoming earnings report date is Apr 06, 2026 which is in 102 days.
How were Precipio Inc’s earnings last quarter?
Precipio Inc released its earnings results on Nov 14, 2025. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.05.
Is Precipio Inc overvalued?
According to Wall Street analysts Precipio Inc’s price is currently Overvalued.
Does Precipio Inc pay dividends?
Precipio Inc does not currently pay dividends.
What is Precipio Inc’s EPS estimate?
Precipio Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Precipio Inc have?
Precipio Inc has 1,752,007 shares outstanding.
What happened to Precipio Inc’s price movement after its last earnings report?
Precipio Inc reported an EPS of -$0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.795%.
Which hedge fund is a major shareholder of Precipio Inc?
Currently, no hedge funds are holding shares in PRPO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precipio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.84%
12-Months-Change
Fundamentals
Return on Equity
-9.76%
Trailing 12-Months
Asset Growth
8.65%
Trailing 12-Months
Company Description
Precipio Inc
Precipio, Inc. (PRPO) is a biotechnology company focused on developing and commercializing innovative diagnostic solutions for cancer and other diseases. The company specializes in providing advanced molecular diagnostics that utilize proprietary technology to enhance the accuracy and efficiency of disease detection and treatment. Precipio's core products include its HemeScreen and HemeTrace tests, designed for hematologic cancers, alongside a range of other diagnostic offerings that cater to various oncological needs.
PRPO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Precipio shows strong financial and operational improvements, particularly in revenue growth and gross margin enhancement. While there were minor setbacks, such as a slight decline in product gross margin and operational challenges faced by the Products division, the company has demonstrated resilience and strategic foresight to overcome these issues. The overall sentiment is positive, with significant progress towards breakeven and strategic initiatives in place to support continued growth.View all PRPO earnings summariesTechnical Analysis
Trinity Biotech
―
DarioHealth
―
BioNano Genomics
―
Intelligent Bio Solutions
―
bioAffinity Technologies, Inc.
―
Ownership Overview
11.09% Insiders
1.50% Mutual Funds
13.00% Other Institutional Investors
73.66% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---